Prospective evaluation of PSMA-targeted 18F-DCFPYL PET/CT in men with biochemical failure after radical prostatectomy for prostate cancer

Steven P. Rowe; Scott P. Campbell; Margarita Mana-Ay; Zsolt Szabo; Mohamad E. Allaf; Kenneth J. Pienta; Martin G. Pomper; Ashley E. Ross; Michael A. Gorin

doi:10.2967/jnumed.119.226514

Prospective evaluation of PSMA-targeted ¹⁸F-DCFPYL PET/CT in men with biochemical failure after radical prostatectomy for prostate cancer

Steven P. Rowe^*, Scott P. Campbell, Margarita Mana-Ay, Zsolt Szabo, Mohamad E. Allaf, Kenneth J. Pienta, Martin G. Pomper, Ashley E. Ross, Michael A. Gorin

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Our purpose is to provide the results of a prospective study evaluating prostate-specific membrane antigen–targeted ¹⁸F-DCFPyL (2-(3-{1-carboxy-5-[(6-¹⁸F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)pentanedioic acid) PET/CT in patients with biochemical failure after radical prostatectomy for prostate cancer (PCa). Methods: Thirty-one patients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 ng/mL and negative conventional imaging results were enrolled in this study and imaged with ¹⁸F-DCFPyL PET/CT. A consensus central review identified foci of radiotracer uptake consistent with sites of PCa. Descriptive statistics were used. Results: Twenty-one patients (67.7%) had at least 1 finding on ¹⁸F-DCFPyL PET/CT consistent with a site of PCa. Imaging was positive in 59.1% of patients with a PSA level of less than 1.0 ng/mL and in 88.9% of patients with a PSA level of more than 1.0 ng/mL. The median SUV_max across all lesions was 11.6 (range, 1.5–57.6). Conclusion: In this prospective study using the prostate-specific membrane antigen–targeted PET agent ¹⁸F-DCFPyL, most patients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low serum PSA levels.

Original language	English (US)
Pages (from-to)	58-61
Number of pages	4
Journal	Journal of Nuclear Medicine
Volume	61
Issue number	1
DOIs	https://doi.org/10.2967/jnumed.119.226514
State	Published - Jan 2020

Funding

This work was funded by Progenics Pharmaceuticals, Inc.; the Prostate Cancer Foundation; National Institutes of Health grants CA134675, CA183031, CA184228, and EB024495; and philanthropy raised by the James Buchanan Brady Urological Institute and Department of Urology. Martin G. Pomper is a coinventor on a patent covering 18F-DCFPyL and is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. He has also received research funding from Progenics Pharmaceuticals, the licensee of 18F-DCFPyL. Michael A. Gorin has served as a consultant to, and has received research funding from, Progenics Pharmaceuticals. Kenneth J. Pienta and Steven P. Rowe have also received research funding from Progenics Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.

Keywords

Biochemical persistence
Biochemical recurrence
Genitourinary
Oncology
PET/CT
Prostate-specific membrane antigen

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2967/jnumed.119.226514

Cite this

@article{f8c0fa0059c74368a596f38954579f5f,

title = "Prospective evaluation of PSMA-targeted 18F-DCFPYL PET/CT in men with biochemical failure after radical prostatectomy for prostate cancer",

abstract = "Our purpose is to provide the results of a prospective study evaluating prostate-specific membrane antigen–targeted 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)pentanedioic acid) PET/CT in patients with biochemical failure after radical prostatectomy for prostate cancer (PCa). Methods: Thirty-one patients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 ng/mL and negative conventional imaging results were enrolled in this study and imaged with 18F-DCFPyL PET/CT. A consensus central review identified foci of radiotracer uptake consistent with sites of PCa. Descriptive statistics were used. Results: Twenty-one patients (67.7%) had at least 1 finding on 18F-DCFPyL PET/CT consistent with a site of PCa. Imaging was positive in 59.1% of patients with a PSA level of less than 1.0 ng/mL and in 88.9% of patients with a PSA level of more than 1.0 ng/mL. The median SUVmax across all lesions was 11.6 (range, 1.5–57.6). Conclusion: In this prospective study using the prostate-specific membrane antigen–targeted PET agent 18F-DCFPyL, most patients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low serum PSA levels.",

keywords = "Biochemical persistence, Biochemical recurrence, Genitourinary, Oncology, PET/CT, Prostate-specific membrane antigen",

author = "Rowe, {Steven P.} and Campbell, {Scott P.} and Margarita Mana-Ay and Zsolt Szabo and Allaf, {Mohamad E.} and Pienta, {Kenneth J.} and Pomper, {Martin G.} and Ross, {Ashley E.} and Gorin, {Michael A.}",

note = "Publisher Copyright: COPYRIGHT {\textcopyright} 2020 by the Society of Nuclear Medicine and Molecular Imaging.",

year = "2020",

month = jan,

doi = "10.2967/jnumed.119.226514",

language = "English (US)",

volume = "61",

pages = "58--61",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "1",

}

TY - JOUR

T1 - Prospective evaluation of PSMA-targeted 18F-DCFPYL PET/CT in men with biochemical failure after radical prostatectomy for prostate cancer

AU - Rowe, Steven P.

AU - Campbell, Scott P.

AU - Mana-Ay, Margarita

AU - Szabo, Zsolt

AU - Allaf, Mohamad E.

AU - Pienta, Kenneth J.

AU - Pomper, Martin G.

AU - Ross, Ashley E.

AU - Gorin, Michael A.

PY - 2020/1

Y1 - 2020/1

N2 - Our purpose is to provide the results of a prospective study evaluating prostate-specific membrane antigen–targeted 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)pentanedioic acid) PET/CT in patients with biochemical failure after radical prostatectomy for prostate cancer (PCa). Methods: Thirty-one patients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 ng/mL and negative conventional imaging results were enrolled in this study and imaged with 18F-DCFPyL PET/CT. A consensus central review identified foci of radiotracer uptake consistent with sites of PCa. Descriptive statistics were used. Results: Twenty-one patients (67.7%) had at least 1 finding on 18F-DCFPyL PET/CT consistent with a site of PCa. Imaging was positive in 59.1% of patients with a PSA level of less than 1.0 ng/mL and in 88.9% of patients with a PSA level of more than 1.0 ng/mL. The median SUVmax across all lesions was 11.6 (range, 1.5–57.6). Conclusion: In this prospective study using the prostate-specific membrane antigen–targeted PET agent 18F-DCFPyL, most patients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low serum PSA levels.

AB - Our purpose is to provide the results of a prospective study evaluating prostate-specific membrane antigen–targeted 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)pentanedioic acid) PET/CT in patients with biochemical failure after radical prostatectomy for prostate cancer (PCa). Methods: Thirty-one patients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 ng/mL and negative conventional imaging results were enrolled in this study and imaged with 18F-DCFPyL PET/CT. A consensus central review identified foci of radiotracer uptake consistent with sites of PCa. Descriptive statistics were used. Results: Twenty-one patients (67.7%) had at least 1 finding on 18F-DCFPyL PET/CT consistent with a site of PCa. Imaging was positive in 59.1% of patients with a PSA level of less than 1.0 ng/mL and in 88.9% of patients with a PSA level of more than 1.0 ng/mL. The median SUVmax across all lesions was 11.6 (range, 1.5–57.6). Conclusion: In this prospective study using the prostate-specific membrane antigen–targeted PET agent 18F-DCFPyL, most patients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low serum PSA levels.

KW - Biochemical persistence

KW - Biochemical recurrence

KW - Genitourinary

KW - Oncology

KW - PET/CT

KW - Prostate-specific membrane antigen

UR - http://www.scopus.com/inward/record.url?scp=85071477277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071477277&partnerID=8YFLogxK

U2 - 10.2967/jnumed.119.226514

DO - 10.2967/jnumed.119.226514

M3 - Article

C2 - 31201249

AN - SCOPUS:85071477277

SN - 0161-5505

VL - 61

SP - 58

EP - 61

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 1

ER -